- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05333718
Characterization of Type 2 Diabetes Subgroups at Diagnosis: a Necessary Step Towards Precision Medicine in Diabetes. (COPERNICAN)
Caracterización de Subgrupos de Diabetes Tipo 2 al diagnóstico: un Paso Necesario Hacia la Medicina de precisión en Diabetes.
Objectives: The primary objective is to identify and characterize the relevant subgroups ( clusters ) in type 2 diabetes (T2DM) at the time of diagnosis in our region. This objective will be addressed using the six main variables (see Methodology) used so far in previous studies in other populations to develop the clustering of diabetes. Therefore, this is a study in diagnostic precision medicine in diabetes. In addition, as secondary objectives, other phenotypic characteristics of these subgroups (clinical, metabolic, and associated comorbidities) will be evaluated.
Methodology: This project will establish a prospective observational cohort study of 1200 subjects newly diagnosed with T2DM in primary care centers in the healthcare areas of Barcelona city and the territory of Lleida. All newly diagnosed cases of T2DM will be identified and evaluated. Participants will undergo a comprehensive phenotypic evaluation, including the six variables that will allow the characterization of T2DM subgroups: age, antibodies against glutamic acid decarboxylase (GAD), body mass index, glycated hemoglobin, and sensitivity indices ( HOMA-IR) and insulin secretion (HOMA beta), based on the determination of C-peptide. The latest generation cluster analysis (k- means and hierarchical clustering ) will be performed, following the method described in previous studies using the six variables mentioned above. Onset diabetes subgroups and their association with secondary outcome variables will be assessed. The initial prescription of antidiabetic medication will be evaluated. Other procedures of this project include: clinical (including complications) and biochemical evaluation, advanced lipoprotein profile, and validated questionnaires to evaluate diet and physical activity.
연구 개요
상세 설명
A multicenter prospective observational study will be conducted. The study design contemplates a single visit that will coincide with the inclusion of the patient in the study. Prior to the inclusion visit, a pre-selection period is planned in which the possible candidate will be invited, all the study procedures will be explained and clarified, the selection criteria will be checked and the inclusion visit will be scheduled.
The scope of the study is made up of Primary Care Centers (CAP) in 2 large health areas (Barcelona and Lleida). In the Annex 8 section, the characteristics and expected recruitment capacity of each CAP are detailed. We have taken a conservative approach using the lower range of incidence calculated based on our own data from 2019 to 2020. The table provided used an expected acceptance rate for participation of 80%. Additionally, CAPs were selected based on commitment and performance in our previous studies. It is planned to include 1200 participants newly diagnosed with T2DM. Depending on compliance with the recruitment rate, the inclusion of other CAPs is possible to achieve the expected number of participants in the study.
Follow-up of participants and linkage with other databases
For this study, a pragmatic follow-up of the participants will be chosen, which is adapted to the usual clinical practice for the follow-up of diabetes. For this reason, the monitoring will be done from:
- SIDIAP/PADRIS databases, with the link to the electronic medical record of the participants who have accepted this option in the informed consent.
- Electronic medical record, in the event that the link with the SIDIAP/PADRIS databases is not possible for technical reasons (non-ICS centers), the collection of monitoring variables will be done directly from the clinical course (review of clinical history) of participants without scheduling additional study follow-up visits.
- For specific causes of mortality, data linkage with the National Institute of Statistics (INE) will be used.
- If the participants have already participated or are participating in other clinical research studies and want to transfer the data they have provided for other projects to this study, this linking (portability) of the data will be allowed.
All participants will be followed until the end of the study, death or withdrawal of informed consent.
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Dídac Mauricio, MD, PhD
- 전화번호: +34935565661
- 이메일: dmauricio@santpau.cat
연구 연락처 백업
- 이름: Bogdan Vlacho, PharmD
- 전화번호: +34 93 207 37 60
- 이메일: bvlacho@santpau.cat
연구 장소
-
-
Catalunya
-
Barcelona, Catalunya, 스페인, 08025
- 아직 모집하지 않음
- Hospital of Santa Creu i Sant Pau
-
연락하다:
- Didac Mauricio, MD, PhD
-
Barcelona, Catalunya, 스페인, 08025
- 모병
- Institut Català de la Salut
-
연락하다:
- Josep Franch-Nadal, MD,PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Subjects of both sexes, of legal age (≥18 years)
- Newly diagnosed T2DM according to the criteria of the American Diabetes Association
- With a maximum duration of three months of the disease at the time of inclusion.
- Writen informed consent
Exclusion Criteria:
Subjects with a new diagnosis of other types of diabetes (type 1, MODY, gestational or other causes) will also be evaluated to ensure that the diagnostic criteria for selection are correctly implemented in all potential study participants.
*For final analysis, subjects with any diagnosis of diabetes other than T2DM will be excluded from the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
Newly diagnosed T2DM
To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population. This objective will be addressed using the 6 main variables that have been used so far in previous studies in other populations to develop disease groupings, that is, age, GAD antibodies, body mass index, glycosylated hemoglobin (HbA1c), and estimates of the evaluation of the homeostatic model 2 of β-cell function and insulin resistance. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
clusters of type 2 diabetes
기간: at inclusion
|
To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population
|
at inclusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
gender clinical characteristics
기간: at inclusion
|
To assess if there are gender diferences among the type 2 diabetes persons at diagnosis
|
at inclusion
|
Frequency of various associated comorbidities, including micro and macrovascular complications
기간: 24 month follow-up period
|
To evaluate and describe the complications of type 2 diabetes during the 24 month follow-up period
|
24 month follow-up period
|
Advanced lipoprotein profile
기간: at inclusion
|
to explore and characterize the lipoprotein profile of the persons with type 2 diabetes at diagnosis
|
at inclusion
|
Lifestyle variables: eating habits and physical activity
기간: at inclusion
|
to explore if there are differences in lifestyle variables such as eating habits and physical activity at diagnosis of type 2 Diabetes Mellitus
|
at inclusion
|
Use in real clinical practice of antidiabetics and other treatments at the beginning of the disease
기간: at inclusion
|
to explore if there are differences in treatment of the antidiabetic drugs and other concomitant medications at diagnosis of type 2 Diabetes Mellitus
|
at inclusion
|
Appearance of different micro- and macro-vascular complications of diabetes
기간: 24 month follow-up period
|
to explore if there are differences in micro and macrovascular complications during the follow-up period related to different sub-types of type 2 Diabetes Mellitus
|
24 month follow-up period
|
Metabolomics and genetic profile related to diabetes
기간: at inclusion
|
to explore if there are differences in Metabolomics and genetic profile related to different sub-types of type 2 Diabetes Mellitus at diagnosis
|
at inclusion
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dídac Mauricio, MD, PhD, Hospital of Santa Creu i Sant Pau
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- IIBSP-CDM- 2021-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제2형 당뇨병에 대한 임상 시험
-
Postgraduate Institute of Medical Education and...완전한
-
Chong Kun Dang Pharmaceutical완전한
-
Sohag Universitysohag university hospital모병
-
Centre hospitalier de l'Université de Montréal...Maisonneuve-Rosemont Hospital모병Boston Keratoprosthesis Type I의 각막 용해캐나다
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
-
Xiang XieXinjiang Medical University아직 모집하지 않음암 | 죽상동맥경화성 심혈관 질환 | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 억제제
-
Jin-Hee AhnAsan Medical Center알려지지 않은HER-2 유전자 증폭 | HER-2 단백질 과발현
-
University of Bologna완전한
-
Tianjin Chest Hospital모병급성관상동맥증후군 | Proprotein Convertase Subtilisin/Kexin Type 9 억제제중국